Treatment of inflammatory disease by cleaving TNF receptors

• US 20050191661A1
• Filed: 12/13/2004
• Published: 09/01/2005
• Est. Priority Date: 11/06/1996
• Status: Abandoned Application

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Gatanaga, Tetsuya, Granger, Gale A.
• Application Number:
  US11/012,047
• Publication Number:
  US 20050191661A1
• Time in Patent Office: Days
• US Class Current: 435/6.18
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/4705 stimulating, promoting or activating activity
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C12N 9/6421 from mammals
• CPC Class Codes: C12N 9/6489 Metalloendopeptidases (3.4.24)
• CPC Class Codes: G01N 2333/525 Tumor necrosis factor [TNF]

Abstract

The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.

Claims

1-32. -32. (canceled)

33. A method for treating arthritis or reducing inflammation in a subject, comprising administering to the subject a means for cleaving TNF receptors from the surface of cells.

34. The method of claim 33, wherein the receptor cleaving means is a protein containing an amino acid sequence encoded in any of SEQ. ID NOs:

1-10, or fragment of any of said amino acid sequences that causes release of TNF receptor from human cells in which TNF is expressed.

35. The method of claim 33, wherein the receptor cleaving means is a protein containing a sequence that is at least 90% identical to an amino acid sequence encoded in SEQ. ID NO:

8, or fragment thereof that causes increased release of TNF receptor from human cells in which TNF is expressed.

36. The method of claim 33, wherein the receptor cleaving means is a protein containing an amino acid sequence encoded in SEQ. ID NO:

8, or fragment thereof that causes increased release of TNF receptor from human cells in which TNF is expressed.

37. The method of claim 33, wherein the receptor cleaving means is an isolated naturally occurring protein obtainable by a process comprising:

a) stimulating THP-1 cells with phorbol myristate acetate;

b) harvesting culture medium from the stimulated cells; and

c) isolating from the medium a protein that causes TNF receptor cleavage.

38. The method of claim 37, wherein the protein has been isolated by a method comprising ion exchange chromatography and separation by molecular weight.

39. The method of claim 37, wherein the protein has been obtained from THP-1, U-937, HL-60, ME-180, MRC-5, Raji, or K-562 cells or normal human monocytes.

40. The method of claim 33, wherein the TNF receptors are human p75 TNF receptors.

41. The method of claim 33, wherein the TNF receptors are human p55 TNF receptors.

42. The method of claim 33, wherein the receptor cleaving means is a protein that is at least about 90% homogeneous when analyzed by SDS polyacrylamide gel electrophoresis.

43. The method of claim 33, comprising administering the protein cleaving means systemically.

44. The method of claim 33, comprising administering the protein cleaving means near the inflammation.

45. The method of claim 34, comprising administering the protein cleaving means intravenously.

46. The method of claim 34, comprising administering the protein cleaving means intramuscularly.

47. The method of claim 33, whereby the subject is treated for sepsis.

48. The method of claim 33, whereby the subject is treated for arthritis.

49. The method of claim 33, whereby the subject is treated for rheumatoid arthritis.

50. The method of claim 33, whereby the subject is treated for multiple sclerosis.